Respiratory sufferers breathing easier
Increased treatment using combination therapies
Sufferers of respiratory diseases, such as asthma and chronic pulmonary disease (COPD), are breathing easier as a result of increased treatments using fixed dose inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combination therapies. The appeal of these combinations is three-fold: improved patient compliance, simplified disease management, and the certainty of bronchodilator and steroid co-administration.
Previously, only two such combination inhalers were available; GSK's Advair/Seretide (fluticasone/salmeterol) and AstraZeneca's Symbicort (budesonide/formoterol). With sales reaching over $4.9 billion in 2005, Advair/Seretide dominates not only its field, but also the total asthma/COPD market. However, a report by Datamonitor, an independent market analyst company, states that Symbicort's recent US approval and Chiesi's recent European approval of an ICS/LABA combination drug, suggest a major change in the market dynamics.
www.datamonitor.com
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
